Project Grant R44AI191984
Award Date 8/21/25
Completion Date 7/31/26
Dollars Obligated $306K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Medford, MA 02155, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,968 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Viva Viral Vaccines, Inc. to develop a broad-spectrum, multivalent vaccine platform for pandemic and seasonal influenza. The platform leverages innovations in the production of influenza neuraminidase (NA) proteins in mammalian cells, enabling the development of VLP-based vaccines that can provide broad heterologous...
- This Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $305,000.00 in funding to Immuno Nano Med, Inc. to demonstrate the feasibility of producing a novel room-temperature-stable, dry-powder inhalable influenza vaccine. The goal is to develop an innovative, next-generation influenza vaccine technology that can promote public health by eliminating the pain points of current flu vaccines, such as the need...
- This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $303,173 to Gateway Bio Inc. to develop a novel stealth lipid formulation for use in an HIV vaccine targeting the membrane-proximal external region (MPER) of the HIV envelope. The goal is to address a key challenge that led to the previous HVTN 133 clinical trial being halted - a polyethylene...
- This $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a GMP-compliant E. coli dihydrofolate reductase (EDHFR) vector. This vector will be used to monitor the biodistribution and trafficking of investigational chimeric antigen receptor (CAR) T cell therapies through positron emission tomography (PET) imaging. The goals are to provide a...
- This federal Project Grant award of $300,000 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a therapeutic nucleic acid vaccine for chronic hepatitis B virus (HBV) infections in HIV/HBV co-infected individuals. The awardee, Orlance, Inc., a woman-owned small business in Seattle, Washington, is leveraging its innovative MACH-1 gene gun technology to efficiently deliver DNA...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), with a CFDA number of 93.855, provides $314,347 in funding to Gateway Bio Inc. for the period from September 23, 2025 to August 31, 2026. The project aims to develop a new lipid nanoparticle (LNP) delivery system for mRNA payloads that uses a proprietary polyethylene glycol (PEG) alternative called POEGMA. This novel LNP is intended to address concerns around PEG-related allergies and reduced...
- This federal Project Grant award of $4,630,686 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop an effective HIV vaccine. The primary goal is to stimulate B cell lineages capable of producing broadly neutralizing antibodies (bnAbs) against diverse HIV strains, a key challenge in traditional vaccine approaches. The research involves preclinical studies in non-human primates using the BG505...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $437,477 to New York University (NYU) to develop a human lymph node-on-a-chip microphysiological system for evaluating the effectiveness of vaccines against infectious diseases. The goal is to create a reliable in vitro model of human lymph nodes that can accurately replicate the immune response process and dynamics,...
- This Project Grant award, totaling $390,942.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The goal of the project is to use self-assembled protein nanocages (SAPNs) as a universal flu vaccine platform to enhance the effectiveness of influenza vaccines. Specifically, the SAPNs will present multiple copies of three highly conserved influenza antigens: trimeric...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, is supporting the development of a unique vaccine to prevent future pandemics caused by emerging coronaviruses. The $755,225 award to Loyola University of Chicago aims to create a T cell-inducing mucosal vaccine targeting conserved coronavirus antigens, which could provide cross-protection against sarbecoviruses and...